47 results about "Colon tumors" patented technology

The invention relates to use of ursolic acid as a colon tumor resistant medicament. The ursolic acid has the effects of inhibiting colon cancer / tumor cell proliferation and inducing apoptosis. In naked mouse in vivo experiments, the ursolic acid can effectively inhibit the proliferation of colon cancer transplanted tumor and inhibit the generation of tumor blood vessels, and has no obvious toxic or side effect on mice. The ursolic acid has the effect of inhibiting EGFR / MAPK signal channel phosphorylation of colon cancer cells, and the key target of the ursolic acid is to inhibit ERK1 / 2 protein phosphorylation. The ursolic acid which is synergetic with oxaliplatin serving as a clinical first-line chemotherapy medicament of the colon cancer has better curative effect. The ursolic acid has better proliferation inhibiting effect on the colon cancer cells of K-RAS gene mutation. The use of the ursolic acid as the colon tumor resistant medicament provides a new thought for treating the colon tumor.

Phage display was used to screen peptide libraries that distinguish between well-differentiated (HCT116) and poorly-differentiated colon carcinoma cells (HT29). The screening protocol used selection and subtraction on intact, viable cells, resulting in phage libraries exhibiting high binding selectivity for the poorly-differentiated HT29 cells. A nine amino acid, disulfide-constrained peptide (RPM) was identified that selectively bound and was internalized into colon cancer cells. The peptide may be used to detect colon cancer cells and also may be used to selectively deliver therapeutic agents to the cells.

Certain cells, including cancer cells such as cells from colon tumors, are capable of expressing BCLP RNA. Targeting using BCLP polypeptides, nucleic acids encoding for BCLP polypeptides, anti-BCLP antibodies, peptides and small molecules provides a method of killing or inhibiting the growth of colon cancer cells that express the BCLP protein. Methods for the diagnosis and therapy of colon tumors that express BCLP are described.

The invention discloses an application of polygonatum polysaccharide in the preparation of drugs for assisting the inhibition of colon cancer. The polygonatum polysaccharide is preferably prepared through the following steps: adopting polygonatum sibiricum as the raw material, extracting the polygonatum sibiricum with boiling water, removing the proteins, carrying out dialysis, and finally carrying out an ethanol treatment so as to obtain the polygonatum polysaccharide. The polygonatum polysaccharide can modulate the tumor micro-environment by inhibiting the tumor from generating new vessels, carrying out immunity inhibition, carrying out anti-oxidation, inhibiting the growth of colon cancer fibroblast, and the like. Thus the polygonatum polysaccharide has a very good auxiliary effect on inhibiting the colon tumor.

The present disclosure relates to a Fusobacterium nucleatum FomA protein vaccine, a preparation method and applications thereof. The preparation method comprises: linking a signal-peptide-sequence-deleted FomA gene linked to a MBP tag to an expression vector, transforming into Escherichia coli, carrying out induced expression, carrying out affinity purification on FomA recombinant protein by usingAmylose Resin High Flow, and carrying out enzyme digestion with a tev enzyme to remove the MBP tag to obtain the Fusobacterium nucleatum FomA protein vaccine. According to the present invention, theFusobacterium nucleatum FomA protein vaccine has good stability, and can effectively improve the immunity of organisms to Fusobacterium nucleatum, improve the survival rate and delay the occurrence and development of colons tumor; and in APCMin / + mice models, the FomA protein vaccine has significant protecting effect on the mice, can be used as a new colon tumor vaccine candidate, and has great application prospects.

The invention relates to monoclonal antibody CAb--1 heavy and light chain variable region gene of human carcinoma of large intestine, the encoded polypeptides by the said genes, and the use of the genes and the polypeptides in preparing the medicament for diagnosis or treatment of colon tumor or rectum tumor, wherein a set of designed expanded primers are introduced. Based on the gene, gene engineering method can be employed to construct and express small molecular genetic engineering antibody of various forms, such as Fab antibody, chimeric antibody, and antibody fusion protein, which can be used in preparing medicament for diagnosis or treatment of large intestine (colon, rectum) cancers.

Disclosed herein are panels related to the diagnosis or recognition of colon and colorectal cancer in a subject. The disclosed panels and related methods are used to predict or assess colon tumor status in a patient. They can be used to determine nature of tumor, recurrence, or patient response to treatments. Some embodiments of the methods include generating a report for clinical management.

A method of predicting the lymphotrophic metastatic potential of a solid non-lymphoid tumor. The percentage of cells of each of a plurality of representative samples of the tumor which express lymphoid gene products is determined. The metastatic potential is predicted to be low when no tumor cells in all of the samples are detected to express lymphoid gene products. The metastatic potential is predicted to be high when a high percentage of tumor cells in at least one of the samples are detected to express lymphoid gene products. Expression of SYKB in any of a plurality of samples of a primary colon tumor is indicative that the primary colon tumor has lymphotrophic metastatic potential.

Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and / or treatment of diseases, particularly colon cancer.

Gene sequences as shown in SEQ ID NO:1-18 have been discovered and isolated, and found to be significantly associated with metastatic spread of breast and colon cancer cells to other organs. Methods are provided for determining the risk of metastasis of a breast or colon tumor, which involve determining whether a tissue sample from a tumor expresses a polypeptide encoded by a gene as shown in SEQ ID NOS:1-18, or a substantial portion thereof. One of the gene sequences encodes a novel aspartyl protease termed CSP56, which can be used to provide reagents and methods for determining which tumors are likely to metastasize and for suppressing metastases of these tumors. Clinicians can use this information to predict which tumors will metastasize to other organs and to provide relevant therapies to appropriate patients.

Aminophosphinic acid derivatives were synthesized as potential inhibitors of renal dipeptidase, an enzyme overexpressed in benign and malignant colon tumors. Several compounds showed potent enzyme-inhibitory activity. These compounds can be used therapeutically and diagnostically for treatment and detection of tumors.

The invention relates to monoclonal antibody CAb--2 heavy and light chain variable region gene of human carcinoma of large intestine, the encoded polypeptides by the said genes, and the use of the genes and the polypeptides in preparing the medicament for diagnosis or treatment of colon tumor or rectum tumor. By introducing a set of designed expanded primers, a strain of monoclonal antibody Cab-2 heavy and light chain variable region gene of human carcinoma of large intestine is cloned from the hybrid tumor cells. The gene can be applied in preparing the medicament for diagnosis or treatment of colon tumor or rectum tumor.

The invention provides a pharmaceutical composition for treating colon cancer and application thereof. The pharmaceutical composition for treating colon cancer consists of 2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}quinazoline-4-yl)amino]-1H-pyrazole-5-yl}-N-(3-fluorophenyl) acetamide and 1,8-dihydroxy-3-carboxyanthraquinone. A compound group and a single drug group provided by the inventionboth have inhibitory effects on a colon cancer cell strain SW1116 in vivo, wherein the tumor inhibitory rate of the compound group is significantly different from that of the single drug group of 2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}quinazoline-4-yl)amino]-1H-pyrazole-5-yl}-N-(3-fluorophenyl) acetamide or the single drug group of 1,8-dihydroxy-3-carboxyanthraquinone; and both groups play a significant synergistic role in inhibiting the proliferation of the colon cancer cell strain SW1116, in which the compound group can inhibit the growth of colon tumor, and the tumor inhibitory rate can reach up to 90.3%.

The invention discloses a traditional Chinese medicine for preventing postoperative recurrence of a colon tumor, and belongs to the technical field of the traditional Chinese medicine. The traditional Chinese medicine is prepared from the following raw materials in parts by weight: 8 parts of astragalus membranaceus, 4 parts of ginseng, 9 parts of Chinese yam, 6 parts of maltose, 6 parts of sea-buckthorn, 3 parts of lilium brownie, 5 parts of semen juglandis, 8 parts of pangolin, 6 parts of malt, 4 parts of poria cocos, 9 parts of angelica sinensis, 2 parts of fruit of Chinese wolfberry, 9 parts of rehmannia, 6 parts of black-bone chicken, 5 parts of euphoria longan, 8 parts of Chinese-date, and 3 parts of liquorice. The medicines are added with honey and water so as to be prepared into traditional Chinese medicine pills. The traditional Chinese medicine adopts pure natural Chinese herbal medicines which are free of toxic and side effects, so that recovery of a gastrointestinal system after a colon tumor surgery is facilitated; the traditional Chinese medicine for strengthening the spleen and stomach is added to assist; the medicines for relieving cancer or tumor symptoms with the effects of invigorating spleen and replenishing qi, enriching the blood and promoting blood circulation, promoting blood circulation to remove blood stasis and the like are combined, so as to achieve the effect of recovering and preventing the postoperative recurrence of tumors.

Disclosed are markers associated with sensitivity to treatment with proteasome inhibitors. Sensitivity is observed when RAS gene is wild type in tumor cells. Compositions and methods are further provided to assess markers of marker genes to predict outcome of treatment using proteasome inhibitors to patients having a solid tumor, such as a lung tumor or a colon tumor.

The invention relates to a hydrogen sulfide intelligent response nanometer material used for chemotherapy and hyperthermia of colon cancer and its preparation method and application. Materials that can combine with endogenous hydrogen sulfide in colon tumors to generate copper sulfide and release chemotherapy drugs at the same time; during preparation, copper-based metal-organic framework nanomaterials that wrap colon cancer chemotherapy drugs are first synthesized, and then coated with polyvinylpyrrolidone on the surface Improve water solubility. Compared with the prior art, the nanomaterial of the present invention can intelligently respond to the endogenous hydrogen sulfide of colon cancer, and trigger photothermal therapy to release colon cancer chemotherapy drugs at the same time. The preparation method is simple and the treatment effect is obvious, and it provides a new diagnosis and treatment reagent for the efficient treatment of colon cancer.